Kornimate/medical-research-clean huggingface dataset:
comparison of micro-dose human chorionic gonadotropin (hcg) with human menopausal gonadotropin (hmg) in polycystic ovary syndrome

Conditions: Endocrine System Diseases; Gonadal Disorders

Summary: the purpose of this study is to compare the effectiveness of low dose human chorionic gonadotropin (hcg) in combination with clomiphen citrate to induce ovulation and its endocrine response in patients who had previously failed to ovulate on clomiphen citrate alone. the investigators will also compare the effectiveness and endocrine response of this approach with the regimen of adding hmg to clomiphen citrate.

infertile women with pcos, who have showed resistance to clomiphen citrate (150 mg- 5 days) in a previous iui treatment cycle at royan institute (infertility and reproductive medicine research centre) will enroll in this prospective randomized clinical trial study and will randomly be divided into three groups. the study protocol will be assessed by an independent institutional review board and royan ethics committee. all subjects will be given the written informed consent. control group (cc/hmg) will receive the 100 mg cc on days 3 to 7 of that cycle but will receive 150 mg human menopausal gonadotropin (hmg) during days of 7, 8, and 9. one of experimental group (group b) will receive a 100 mg dose of cc but will receive a 200 iu human chorionic gonadotropin (hcg; choriomon; ibsa, switzerland) intramuscular injection daily when the largest follicle is 12 mm or larger mean diameter. other experimental group (group c) will receive a 100 mg dose of cc but will receive a 200 iu human chorionic gonadotropin (hcg; choriomon; ibsa, switzerland) intramuscular injection daily from day 9(without attention to follicle size). in both experimental groups hcg administration will be continued until the largest follicle is 18-20 mm. ultrasound measurements of follicle number and growth, ovulation, gestational sac, and serum hormonal levels will be recorded and compared between two groups.

Eligibility criteria:
inclusion criteria: * women with pcos diagnosed by the rotterdam criteria * previously documented dominant follicle or follicles (r12 mm mean diameter) on transvaginal ultrasound follicular monitoring while receiving cc at the 150-mg dose in our clinic but have failed to ovulate; * primary infertility * documented normal uterine cavity and patent tubes by either hysterosalpingogram or laparoscopy and hysteroscopy; * male partner had to have a normal semen analysis by world health organization criteria. exclusion criteria: * previous history of ivf or icsi treatments. * history of hormonal treatment within recent three month (except ocp, progesterone). * history of ovarian cutter or ovarian drilling. * bmi higher than 30. * the presence of ovarian cyst (more than 30 mm) during third cycle ultrasound.

Keywords: human chorionic gonadotropin clomiphene citrate chronic anovulation polycystic ovary syndrome follicolugenesis
valvular aortic stenosis prognosis study

Conditions: Morality

Summary: aortic stenosis is the most common valvulopathy in western countries. cardiac echodoppler is the reference method for assessment of aortic stenosis and provides prognostic elements. however, it is imperfect with many inconsistencies between measures. on the other hand, the prognosis of patients with low flow and low gradient aortic retraction is discussed. the main objective of this work is to study the prognosis of asymptomatic and symptomatic aortic retraction.

aortic stenosis is an attack most often acquired from the aortic valve corresponding to a defect of opening of this valve. its prevalence increases with age and approaches 2% at age 65 and 25% at age 85 . it is in the majority of cases degenerative due to the development of calcifications on the aortic sigmoid valves by a process close to atherosclerosis (otto cm, circulation, 1994). it is associated with cardiovascular risk factors (age, male sex, smoking, high blood pressure and associated high ldl cholesterol). aortic stenosis may also frequently be the consequence of aortic bicuspid (congenital) or more rarely rheumatic fever. aortic stenosis is responsible for an obstacle to ejection of the left ventricle with increased afterload and thus left ventricular work. after a long asymptomatic period when the obstacle to ejection is compensated by the induction of an adaptive left ventricular hypertrophy, symptoms appear initially of effort (dyspnea, angina, lipothymia see syncope) then clinical signs of insufficiency heart. the occurrence of symptoms should cause aortic valve replacement because at this stage the prognosis becomes unfavorable with a risk of death by cardiac decompensation or sudden death. the two pillars of the diagnosis of severity are the evaluation of functional aortic valve area and the average transvalvular gradient. the tight aortic stenosis is defined for a functional aortic area \ 40 mmhg. patient survival data and / or a possible complication or indication for surgery will be evaluated periodically either during a standard follow-up consultation if patients are followed in the referral center or by telephone contact with the attending physician or cardiologist. . in case of death, the cause and date will be collected.

Eligibility criteria:
inclusion criteria: * retrospectively, all patients examined from january 1, 2000 to november 2014 will be included in the echocardiography laboratory whose objective examination is a narrowing of the aortic valve (maximum transaortic velocity ≥2.5 m / s). * aortic stenosis may be known in the past. exclusion criteria: * refusal of the patient to participate in the study. * patients who have previously had aortic valve surgery before being examined in the echocardiography laboratory. * patients who can not be contacted or who do not respond will not be included in the database.

Keywords: echoacrdiography echodoppler aortic valve stenosis prognosis
safety and efficacy of a weekly oral cyclic antibiotic programme in the prevention of urinary tract infection on neurological bladder

Conditions: Neurogenic Bladder; Urinary Tract Infection

Summary: symptomatic urinary tract infections (utis) are one of the main causes of morbidity and the main cause of re-hospitalization in subjects with neurogenic bladder. long-term antibiotic therapy increases the risk of multi-resistant bacterial infections, without reducing the rate of symptomatic utis. our non-comparative preliminary study has shown that weekly oral cyclic antibiotic programme (single, weekly dose of antibiotic x on even weeks, and antibiotic y on odd weeks) seem to drastically reduce both the number of symptomatic utis and the number of hospitalizations in patients with neurogenic bladder, without affecting bacterial ecology. the objective of this study is to validate this preliminary work with a large-scale randomized, parallel-group, multicenter study.


Eligibility criteria:
inclusion criteria: * subject over 18 years of age * having a neurogenic bladder with automatic catheter and pharmacologic disconnection of the detrusor muscle * having at least 4 symptomatic utis per year with bacterial sensitivity to the chosen antibiotics * having given full consent to participate in the study * being the recipient of social security benefits exclusion criteria: * known allergy or hypersensitivity to useful antibiotics (to which the bacterium or bacteria are sensitive) or to one of their components * other contraindication in the administering of useful antibiotics * urinary volume flow \>500 ml during automatic catheter * different urinary drainage method than automatic catheter * occurrence of stones in the urinary tract * infection due to endo urinary material (urinary prosthesis, ureteral stent) * creatinine clearance \<60 ml/min * patient under guardianship * women who are pregnant, nursing, or who may become pregnant

Keywords: neurogenic bladder urinary tract infection
comparing total laparoscopic versus open pancreaticoduodenectomy

Conditions: Pancreatic Ductal Adenocarcinoma; Surgery; Periampullary Cancer

Summary: introduction pancreatoduodenectomy (pd) is one of the most complex abdominal operations to perform, and it is usually conducted for tumours of the periampullary region and chronic pancreatitis. minimally invasive surgery has been progressively being developed for pancreatic surgery, first with the advent of hybrid-laparoscopy and recently with total laparoscopic surgery. issues including the safety and efficacy of total laparoscopic pancreaticoduodenectomy (tlpd) and open pancreaticoduodenectomy (opd) are currently being debated. studies comparing these two surgical techniques are emerging, and large randomized controlled trials (rcts) are lacking but are clearly required. methods and analysis tjdbps01 is a multicentre, prospective, randomized controlled, parallel-group, superiority trial in fourteen centres with pancreatic surgery experts who have performed ≥104 tlpds and opds. a total of 656 patients who will undergo pd are randomly allocated to the tlpd group or opd group in a 1:1 ratio. the trial hypothesis is that tlpd has superior or equivalent safety and advantages in postoperative recovery compared with opd. the primary outcome is the postoperative length of stay (los). ethics and dissemination the instituitional review board approval of tongji hospital, tongji medical college, huazhong university of science and technology has approved this trial and will be routinely monitoring the trial at frequent intervals, as will an independent third-party organization. any results from this trial (publications, conference presentations) will be published in peer-reviewed journals and conference proceedings.


Eligibility criteria:
inclusion criteria: 1. histologically proven periampullary cancer, including pancreatic cancer, bile duct cancer, duodenal cancer, et al. 2. highly presumed malignancy with difficulties to obtain histological evidence. 3. preoperative staging work up performed by upper abdomen enhanced ct scan. 4. the subject understands the nature of this trial and willing to comply. 5. ability to provide written informed consent. 6. patients treated with curative intent in accordance to international guidelines exclusion criteria: 1. distant metastases: peritoneal carcinomatosis, liver metastases, distant lymph node metastases, involvement of other organs. 2. subjects undergoing left, central or total pancreatectomy. 3. patients with high operative risk as defined by the american society of anesthesiologists (asa) score \>4. 4. synchronous malignancy in other organs. 5. previous underwent pancreatic resections. 6. palliative surgery.

Keywords: pancreaticoduodenectomy surgical outcome
the effect of gluten on gut microbiome and metabolic health.

Conditions: Metabolic Diseases; Injury of Gastrointestinal Tract

Summary: objective: to identify how specific changes of the gluten content in the diet affect the host-gut microbiome interactions with implications for metabolic health. design: a randomized, controlled, single-blinded, cross-over intervention trial consisting of two 8-week interventions periods, separated by a 6-week wash-out period. a total number of 60 participants will be included. intervention: low vs high gluten intake.

the study is designed as a randomized, controlled, single-blinded, cross-over intervention trial consisting of two 8-week interventions periods, separated by a 6-week wash-out period. a total number of 60 participants will be included. participants consume, in randomized order, a gluten-poor diet (\ 25 g/d) during the control period. measurements: altered quantitative metagenomics at bacterial gene- and species levels is the primary outcome of this study. secondary outcomes include metabolic and inflammatory markers, circulating appetite hormone levels,serum metabolomics, gastrointestinal transit time and intestinal permeability. furthermore, selected control measures are included; 4-day food records and a study intervention dietary records.

Eligibility criteria:
inclusion criteria, compulsory: * body mass index (bmi): 25 - 35 kg/m2 or * abdominal obesity: waist circumference: men: ≥ 94cm; women: ≥ 80cm * no medically prescribed diet * weight stable * intense sporting activities less than 10 h/week * alcohol consumption less than 14 units/week (female) and 21 units/week (male) * signed informed consent inclusion criteria, minimum one of the following: * fasting plasma glucose from 6.1 mmol/l to 6.9 mmol/l * reduced high density lipoprotein (hdl) cholesterol; hdl ≤ 1.03 mmol/l for men and ≤ 1.29 mmol/l for women * increased triglyceride (tg) \> 1.3 mmol/l * systolic blood pressure \> 130 mmhg exclusion criteria: * pharmacological treatment; diabetes and blood lipid regulation * lactating (or lactating, 6 weeks ago), pregnant (or pregnant, 3 months ago) or wish to become pregnant during the study * participation in another biomedical trial 1 month prior to study start * diagnosed with any form of diabetes, celiac disease or chronic pancreatitis * reported chronic gastrointestinal disorders * antibiotic treatment for 3 month prior to study start * blood hemoglobin \< 7.0 mmol/l * blood donation within 1 month prior to study start
neuramis® volume lidocaine for volume augmentation in the mid-face

Conditions: Mid Face Volume Loss

Summary: to evaluate the effectiveness and safety of neuramis® volume lidocaine for volume augmentation in the mid-face.

this is a multicenter, randomized, evaluator-blinded, "no-treatment" controlled study conducted in normal, healthy subjects. this study is anticipated to enroll approximately 236 male and/or female subjects between the ages of 20 to 75 years, inclusive, who desire volume augmentation to correct deficit in their mid-face volume.

Eligibility criteria:
inclusion criteria: 1. male or female 20 to 75 years of age 2. subjects who desire volume augmentation to correct deficit in the mid-face volume that is rated as grade 3, 4, or 5 on the facial volume scale exclusion criteria: 1. subjects who have received anti coagulation, anti-platelet, or thrombolytic medications, anti-inflammatory drugs. 2. subjects who have undergone facial plastic surgery in the face area below the level of the lower orbital rim, tissue grafting, or tissue augmentation with silicone, fat, or other permanent, or semi-permanent dermal fillers or are planning to undergo any of these procedures at any time during the clinical investigation.
bortezomib for immunoglobulin light chain(al) amyloidosis

Conditions: Amyloidosis

Summary: although the use of bortezomib has reported efficacy in amyloid light chain (al) amyloidosis, the role of bortezomib with dexamethasone (bd) in the first-line treatment of patients with al amyloidosis should be determined. in this study, the investigators evaluated the efficacy and safety of bd as the first-line treatment of patients with al amyloidosis.

this study included patients with newly diagnosed al amyloidosis who were treated with a bd regimen in jinling hospital. the al amyloidosis diagnosis was confirmed by renal biopsy, and the assessment of organ involvement were based on consensus criteria. the clinical and laboratory data were collected at the beginning of each cycle and every 3 months thereafter. the initial bd regimen included bortezomib (1.3 mg/m2 i.v.) and dexamethasone (40 mg i.v.) twice weekly for 2 weeks (days 1, 4, 8, and 11), which was followed by a 10-day rest period (days 12-21). the investigators evaluated the efficacy and safety of bd as the first-line treatment of patients with al amyloidosis.

Eligibility criteria:
inclusion criteria: * female or male patients aged between 18 to 80 years * renal or other type biopsy was used to diagnose al amyloidosis * understand and voluntarily sign an informed consent form * ecog score 0-3 points * adequate residual organ function exclusion criteria: * receiving any other investigational agent which would be considered as a treatment for the primary neoplasm * grade 3 sensory or grade 1 painful peripheral neuropathy * known hypersensitivity to bortezomib, boron or mannitol * cardiac syncope, uncompensated new york heart association (nyha) class 3 or 4 congestive heart failure * clinically overt multiple myeloma * pregnant or nursing women.
effects of probiotic mixture supplementation and evaluation of intestinal mucosal tolerance and gut microbiome in newborns with perinatal asphyxia receiving hypothermic treatment

Conditions: Asphyxia Neonatorum; Morbidity;Newborn

Summary: the visnat trial is a pilot study due to absence of previous evidences in literature on using probiotic in newborns with perinatal asphyxia. it is designed as a randomized, placebo-controlled, blinded, multicentre superiority trial with two parallel groups and a primary outcome of mortality and/or disability at 18 months of age. after informed consent is obtained from both parents, randomization will be performed as block randomization with a 1:1 allocation using a computer-generated allocation sequence, while the allocation concealment will be performed using locked bags. randomization data and allocation list will be stored in a secure place and will not be available to any of the components of the study apart of data collectors. participant files will be stored for a period of 10 years after completion of the study. all the components of the study will be blinded including: participants and their parents, healthcare providers, outcome assessors, data collectors, data analysts.


Eligibility criteria:
inclusion criteria: * o newborns with gestational age \>/= 35 weeks and birth weight \>/= 1800 grams o intrapartum asphyxia defined according at least one of the following: * apgar index at 10 minutes \</=5; * resuscitation with endotracheal tube or mask ippv for more then 10 minutes; * ph \ /= 12 mmol/l on arterial blood gas (abg) analysis within the first 60 minutes of life * moderate/severe hypoxic-ischemic encephalopathy assessed between 30 and 60 minutes of life according to sarnat \& sarnat definition * hypothermic treatment. according to the italian national guidelines on perinatal asphyxia and therapeutic hypothermia, the hypothermic therapy will be started in the first six hours of life and will last 72 hours. exclusion criteria: * inability to obtain the informed consent from both parents * congenital major malformations or syndromes o surgical diseases
fecal microbiota transplant by oral capsules with lactobacilli for recurrent clostridium difficile infection

Conditions: Clostridium Difficile Infection

Summary: investigators designed an open, two-arm study to compare fecal microbiota transplant by oral capsules (fmt-c ) versus fmt-c enriched with lactobacillus for treatment of c. difficile recurrent infection

investigators designed an open, two-arm study to compare to compare fecal microbiota transplant by oral capsules (fmt-c ) versus fmt-c enriched with lactobacillus for treatment of c. difficile recurrent infection. from each patient, a fecal sample was obtained at days 0, 3, and 7 after treatment. fecal samples are analyzed by 16 subunit ribosomal ribonucleic acid (16s rrna) metagenomic sequencing.

Eligibility criteria:
inclusion criteria: * older than 18 years with recurrent cdi exclusion criteria:older than 18 years -
the effect of panax notoginseng powders on rheumatic pain

Conditions: Rheumatic Pain

Summary: the purpose of this study is to evaluate the effect of panax notoginseng powders on rheumatic pain.


Eligibility criteria:
inclusion criteria: * had a diagnosis of classic or definite ra * without conflict to the written, informed consent signed prior to the enrollment. exclusion criteria: * uncontrolled medical problems * organic brain syndrome * major psychiatric disturbances * major communicative disorders * a history of severe noncompliance * less than 7 years of formal education, or illiteracy * being included in other clinical trial within the last 4 weeks * with abnormal liver or kidney function (more than 1 time above the high normal) * with serious cardiovascular disease * with hematologic disease * being in pregnancy, lactation period or under a pregnancy plan * with severe gastrointestinal disease * with contraindication or being allergic to the test drugs * being under the treatment of drugs within 1 previous week, that might affect the results of the trial, such as non-steroidal anti-inflammatory drugs * being not compatible for the trial medication, or other circumstances at the discretion of investigators * without legal capacity or only with limited legal capacity
selective versus stepwise removal of deep carious lesions in permanent teeth using different medicaments

Conditions: Caries Arrested

Summary: the study involved 54 adult patients between the ages of 18 and 50 years who had a posterior permanent tooth with a deep occlusal (class i) carious lesion that extended to the inner third of the dentin (d3) and divided them into two equal groups randomly (n=27) according to the caries removal technique: group 1 (se), and group 2 (sw). then each main group was equally subdivided into three equal subgroups (n=9) according to the applied dentin dressing material as follows: subgroup 1: nano-silver compound (nsc), subgroup 2: chitosan-loaded nano hydroxy apatite (cs/n-hap), subgroup 3: bioactive glass ionomer (n-bag/gic). at the first visit both groups received the same treatment of incomplete caries excavation, application of dentin dressing materials and sealing temporarily for 3-months with a glass ionomer cement (gic). at the second visit the gic reduced pulpally in (se) group leaving 2 mm as base and completely removal the remaining carious lesion in (sw) group then re-application of same dentin dressing material on each tooth and gic as a base. finally, all cavities were restored with selective enamel etching technique, after which self-etch adhesive and nano-filled composite resin are applied according to manufacturer instructions. the clinical and digital radiographic evaluations of the success and failure rates were performed at: baseline (7 days), 3, 12, and 18-months.


Eligibility criteria:
inclusion criteria: 1. patients with first and second molars with occlusal deep carious lesions (class i) extending to the inner third of dentin thickness on radiographic examination using (i-sensor h1, woodpecker, china). 2. teeth with a healthy response to the electrical pulp tester (dy 310, denjoy dental co., ltd, china). 3. teeth with the absence of spontaneous pain. 4. teeth with a negative sensitivity to percussion. 5. teeth with the absence of periapical lesions by a digital radiographic examination. 6. clinically, all teeth were without any mobility. 7. patients who will complete the procedure of follow up. 8. patients who will sign the consent. exclusion criteria: 1. mutilated teeth or teeth with caries extending subgingivally. 2. teeth with the existence of previous restorations. 3. teeth with periodontal disease, any swelling, fistulas, signs of irreversible pulpitis or necrotic pulp. 4. teeth with roots showing external or internal resorption. 5. pregnant women. 6. presence of any systemic disease.
effectiveness and safety of acupuncture for obesity and over-weight people

Conditions: Obesity; Overweight

Summary: to determine the efficacy and safety of acupuncture for obesity and overweight people in china.


Eligibility criteria:
inclusion criteria: * the individuals is phlegm-dampness constitution and female. * age is between 18 and 45 years. * bmi is between 24 and 50. * the individuals voluntarily sign the informed consent form. * the individuals live in harbin city of china. exclusion criteria: * secondary obesity, eg:pituitary diseases, hypothalamic disorder, hypothyroidism, pancreatic diseases，hyperadrenocorticism, postmenopausal obesity etc. * the individuals with server cardiovascular and cerebrovascular diseases and cancer. * having therapy for obesity in the last three months. * the individuals do not adhere to the treatment or are with other treatments. * female individuals with pregnancy, lactation and planning a pregnancy in the two months. * critical patients or patients combined with liver and kidney damage. * individuals with visual and auditory memory disorders or psychosis.

Keywords: acupuncture chinese traditional medicine